Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2018-05-25 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
PrimaryBid.com Offer
Regulatory Filings Classification · 98% confidence The document is an announcement from Mereo BioPharma Group plc regarding a new share offering via the PrimaryBid platform. It details the issuance of new ordinary shares, the purpose of the capital raise (to broaden the shareholder base for a Nasdaq listing), and the mechanics of the offer. This falls under the category of capital raising and financing activities. While it mentions an Annual Report, it is merely a reference link, not the report itself. Therefore, it is classified as a Capital/Financing Update.
2018-05-25 English
Notice of AGM
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) from Mereo BioPharma Group plc regarding the upcoming Annual General Meeting (AGM). It provides the date, time, and location of the meeting and directs readers to the company's website to access the full Notice of Annual General Meeting. Per the 'Menu vs Meal' rule, this is an announcement of a report/notice rather than the document itself, and it serves as a notification of an upcoming event, fitting the Report Publication Announcement (RPA) category.
2018-05-22 English
Grant of Options
Director's Dealing Classification · 100% confidence The document is an official notification regarding the grant of share options to directors and persons discharging managerial responsibilities (PDMRs). It explicitly references Article 19 of the Market Abuse Regulation (EU) No 596/2014, which governs notifications of transactions by persons discharging managerial responsibilities. While it mentions remuneration, the primary purpose is the disclosure of specific insider/director dealings (grant of options), which falls under the 'Director's Dealing' category.
2018-04-27 English
Update on Offering & Application to List on Nasdaq
Regulatory Filings Classification · 98% confidence The document is an official announcement from Mereo BioPharma Group plc regarding the withdrawal of a global offering and the postponement of a Nasdaq listing. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it discusses capital-related activities, it is a regulatory announcement of a corporate event rather than a formal prospectus or a financial report. Given the RNS header and the nature of the announcement, it falls under the 'Regulatory Filings' category.
2018-04-26 English
Regulatory Filings 2018
Regulatory Filings
2018-04-18 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is not a financial report, earnings release, or management discussion. The document primarily registers securities for listing on Nasdaq and includes descriptions of the securities and related information. It does not contain financial statements or detailed financial data. Given the nature of the filing, it is a regulatory announcement related to securities registration and does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. The best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory documents that do not fit other categories. The document length is 4221 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2018-04-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.